Compare · COR vs HKPD
COR vs HKPD
Side-by-side comparison of Cencora Inc. (COR) and Cellyan Biotechnology Co. Ltd (HKPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COR and HKPD operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- COR is the larger of the two at $53.33B, about 4640.4x HKPD ($11.5M).
- Over the past year, COR is down 3.5% and HKPD is down 77.7% - COR leads by 74.2 points.
- COR has been more active in the news (5 items in the past 4 weeks vs 4 for HKPD).
- COR has more recent analyst coverage (25 ratings vs 0 for HKPD).
- Company
- Cencora Inc.
- Cellyan Biotechnology Co. Ltd
- Price
- $274.18-0.32%
- $0.48-5.73%
- Market cap
- $53.33B
- $11.5M
- 1M return
- +7.28%
- -21.31%
- 1Y return
- -3.46%
- -77.67%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 5
- 4
- Recent ratings
- 25
- 0
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
Latest COR
- Cencora Inc. filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form SD filed by Cencora Inc.
- Director Durcan Dermot Mark bought $1,065,040 worth of shares (4,000 units at $266.26), increasing direct ownership by 17% to 27,767 units (SEC Form 4)
- Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer
- Cencora Announces Updated Fiscal Year 2026 Financial Outlook
- SEC Form 10-Q filed by Cencora Inc.
- Cencora Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Cencora Reports Fiscal 2026 Second Quarter Results
- Director Tyler Lauren M was granted 99 shares, increasing direct ownership by 3% to 3,809 units (SEC Form 4)
- Director Cooper Ellen was granted 99 shares, increasing direct ownership by 14% to 796 units (SEC Form 4)
Latest HKPD
- SEC Form 3 filed by new insider Liu Shu
- SEC Form 3 filed by new insider Zhou Mike Yao
- SEC Form 3 filed by new insider Wu Jingyan
- SEC Form 3 filed by new insider Liang Chenyu Andy
- SEC Form EFFECT filed by Cellyan Biotechnology Co. Ltd
- SEC Form F-1 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency